Recent development of lipoxygenase inhibitors as anti-inflammatory agents

MedChemComm
2017.0

Abstract

Inflammation is favorable in most cases, because it is a kind of body defensive response to external stimuli; sometimes, inflammation is also harmful, such as attacks on the body's own tissues. It could be that inflammation is a unified process of injury and resistance to injury. Inflammation brings extreme pain to patients, showing symptoms of rubor, swelling, fever, pain and dysfunction. As the specific mechanism is not clear yet, the current anti-inflammatory agents are given priority for relieving suffering of patients. Thus it is emergent to find new anti-inflammatory agents with rapid effect. Lipoxygenase (LOX) is a kind of rate-limiting enzyme in the process of arachidonic acid metabolism into leukotriene (LT) which mediates the occurrence of inflammation. The inhibition of LOX can reduce LT, thereby producing an anti-inflammatory effect. In this review, the LOX inhibitors reported in recent years are summarized, and, in particular, their activities, structure-activity relationships and molecular docking studies are emphasized, which will provide new ideas to design novel LOX inhibitors.

Knowledge Graph

Similar Paper

Recent development of lipoxygenase inhibitors as anti-inflammatory agents
MedChemComm 2017.0
5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach
Bioorganic & Medicinal Chemistry 2019.0
Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents
Bioorganic & Medicinal Chemistry 2007.0
Synthetically-tailored and nature-derived dual COX-2/5-LOX inhibitors: Structural aspects and SAR
European Journal of Medicinal Chemistry 2021.0
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities
European Journal of Medicinal Chemistry 2011.0
4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)
European Journal of Medicinal Chemistry 2016.0
Synthesis, in silico docking experiments of new 2-pyrrolidinone derivatives and study of their anti-inflammatory activity
Bioorganic & Medicinal Chemistry 2011.0
5-Lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors
Journal of Medicinal Chemistry 1992.0
Benzoxepin and benzothiepin derivatives as potent, orally active inhibitors of 5-lipoxygenase
Bioorganic & Medicinal Chemistry Letters 1994.0
Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and proinflammatory cytokines
Bioorganic & Medicinal Chemistry 2014.0